An Opening for Justice: ALLR Investors in the Limelight
LOS ANGELES, Oct. 3, 2024 /PRNewswire/ — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR faces a potential reckoning as investors are given the rare opportunity to lead the charge in a securities fraud class action lawsuit against the Company.
Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024
The lawsuit alleges that Allarity failed to disclose critical information to investors during the Class Period, including significant overstatements regarding the regulatory prospects of Dovitinib NDA. The veil over alleged illegal and improper conduct surrounding Dovitinib NDA and the Dovitinib-DRP PMA by Allarity and its former officers is also a focal point of the complaint. This opacity exposed the Company to heightened risks of regulatory scrutiny and legal repercussions, potentially tarnishing its reputation and finances. Moreover, the lawsuit claims that following an announcement of an investigation into the same, Allarity downplayed the impending consequences. The defendants’ purportedly misleading statements on the Company’s business operations further exacerbate the situation.
To stay abreast of updates, investors can consider following LinkedIn, Twitter, or Facebook.
For those claiming membership in the class action, no immediate action is required. Decision-making power remains with the individual to engage legal counsel or retain observer status. Seeking more information on the lawsuit or clarifications pertinent to rights and interests can be obtained by contacting Charles Linehan, Esquire of GPM, situated in Los Angeles, or by visiting the official website of Glancy Prongay & Murray LLP.
As this press release may be perceived as Attorney Advertising in certain jurisdictions, legal compliance adheres to regional legislations.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
